Move beyond averages

Break out of the limitations of bulk sequencing
for precision medicine.

Today's conventional technology for measuring cellular mutations and heterogeneity for complex disease is bulk sequencing based on averages. However, the problem with averages is that the underlying genetic diversity is missed across cell populations. Understanding this diversity is important for patient stratification, therapy selection, and disease monitoring. Moving beyond averages helps to deliver on the promise of precision medicine.

MISSION BIO REVEALS
MUTATION CO-OCCURRENCE

SEE WHAT YOU’RE MISSING

The promise of precision medicine is to deliver highly targeted treatment to every single diseased cell.

The current one-size-fits-all approach of medical treatments isn’t working for many patients who need help. To move precision medicine forward, researchers and clinicians need to look at the origins of disease — the single cell — in meaningful new ways.

Because most diseases are not caused by just one mutation, understanding genetic variability — including mutation co-occurrence at the single-cell level — is vitally important for clinical researchers. However, this level of resolution is missed with existing bulk sequencing which can result in failed clinical trials, high costs, and poor patient outcomes.

To impact precision drug discovery, development, and delivery, we need insight into the mutational differences with and among every single cell.

THE DNA DIFFERENCE

Accessing DNA on the single-cell level and leveraging its molecular stability is key to making meaningful discoveries that can drive precision medicine.

Reliably identify
mutations within a cell

Accurately pinpoint
sub-clonal populations

Enable better therapy
selection and disease monitoring

Meet Tapestri

the Precision Genomics Platform

Perform scalable, customizable, single-cell DNA analysis.

The Mission Bio Tapestri Platform was developed to help advance precision medicine by enabling the accelerated and accessible detection of genomic variability within and across cell populations. Leveraging proprietary drop microfluidics, the platform unlocks access to DNA at the single-cell level with a novel two-step protease workflow. This methodology provides flexibility for additional applications and customization capability.

HOW TAPESTRI WORKS

Our revolutionary platform plugs seamlessly into existing next-generation sequencing (NGS) workflows and includes the instrument, consumables, and software for downstream analysis.

  • Cell
    Preparation
  • Cell Encapsulation
    + Protease Addition
  • Cell Barcoding +
    Reagent Addition
  • Downstream LIB
    Prep + NGS
  • Data Analysis +
    Visualization Software

Cell Preparation

Prepare a single-cell suspension to run on the Tapestri System.

Cell Encapsulation + Protease Addition

Tapestri Instrument partitions cells into droplets along with a protease enzyme mix. Cell lysis and protease digestion then follow off-instrument enabling access to DNA for downstream amplification.

Cell Barcoding + Reagent Addition

The cell lysate is then combined with barcoded beads, primers, and reagents. Specific regions of interest are then amplified while tagging each amplicon with a unique cell barcode, preserving the cell’s identity and its mutational profile.

Downstream LIB Prep + NGS

Standard library prep follows, where sequencing adapters are added, followed by sequencing on the Illumina MiSeq System.

Data Analysis + Visualization Software

After running your sequencer, proceed with our downstream analysis and visualization software. Mission Bio provides dedicated bioinformatics support to help you discover biological and clinical insights.

TAPESTRI IN ACTION

With the first application in acute myeloid leukemia (AML) targeting 19 genes with 40 amplicons, single nucleotide variant (SNV) and indel mutation detection at the single-cell level can now occur at unprecedented scale.

“In studying leukemias, we are excited about now having the ability to genotype multiple mutations at single-cell resolution in this level of high throughput.  Otherwise, the average readout from bulk sequencing misses these important insights in cellular heterogeneity. This new capability of single-cell analysis is critical to better understanding precision therapy selection at diagnosis as well as disease monitoring and subsequent treatment strategy.”

Koichi Takahashi, MD, Assistant Professor
MD Anderson Cancer Center

Discovery is in our DNA

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics.

In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team.

Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine.

play

CURRENT INVESTORS

Mission Bio is proud to have support from these major investors.

Get in touch

Let’s work together to advance precision medicine.

required*

Your message has been sent successfully